Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America
- PMID: 34133774
- PMCID: PMC8895675
- DOI: 10.1002/hep.32018
Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America
Abstract
Background and aims: The clinical utility of two biomarkers, hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg), as compared to conventional markers of HBV replication and disease activity, is unclear.
Approach and results: Untreated participants in the North American Hepatitis B Research Network Adult Cohort Study were categorized by chronic hepatitis B (CHB) phases based on HBsAg and HBeAg status and HBV DNA and alanine aminotransferase (ALT) levels. HBV RNA and HBcrAg were measured (Abbott HBV pgRNA Research Assay and Fujirebio Lumipulse Immunoassay, respectively), and cross-sectional associations with conventional CHB markers were tested. Among 1,409 participants across all CHB phases, median HBV DNA was 3.8 log10 IU/mL and ALT was 34 U/L. HBV RNA was quantifiable in 99% of HBeAg+ and 58% of HBeAg- participants; HBcrAg was quantifiable in 20% of HBeAg+ (above linear range in the other 80%) and 51% of HBeAg- participants. Both markers differed across CHB phases (P < 0.001), with higher levels in the HBeAg+ and HBeAg- immune active phases. HBV RNA and HBcrAg correlated moderately strongly with HBV DNA in both HBeAg+ and HBeAg- phases (HBV RNA: e+ ρ = 0.84; e- ρ = 0.78; HBcrAg: e+ ρ = 0.66; e- ρ = 0.56; P for all, <0.001), but with HBsAg levels among HBeAg+ phases only (HBV RNA: e+ ρ = 0.71; P < 0.001; e- ρ = 0.18; P = 0.56; HBcrAg: e+ ρ = 0.51; P < 0.001; e- ρ = 0.27; P < 0.001). Associations of higher HBV RNA and HBcrAg levels with higher ALT, APRI, and Fibrosis-4 levels were consistent in HBeAg- , but not HBeAg+ , phases.
Conclusions: Despite clear relationships between HBV RNA and HBcrAg levels and CHB phases, these markers have limited additional value in differentiating CHB phases because of their strong association with HBV DNA and, to a lesser extent, with clinical disease indicators.
© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This article has been contributed to by US Government employees and their work is in the public domain in the USA.
Figures




Comment in
-
Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.Hepatology. 2022 Mar;75(3):760-761. doi: 10.1002/hep.32250. Epub 2022 Jan 9. Hepatology. 2022. PMID: 34800036 No abstract available.
-
Reply.Hepatology. 2022 Mar;75(3):761-763. doi: 10.1002/hep.32251. Epub 2021 Dec 21. Hepatology. 2022. PMID: 34800047 No abstract available.
-
Reply.Hepatology. 2022 Mar;75(3):764-765. doi: 10.1002/hep.32253. Epub 2021 Dec 18. Hepatology. 2022. PMID: 34800052 No abstract available.
Similar articles
-
Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients.J Med Virol. 2021 Jun;93(6):3688-3696. doi: 10.1002/jmv.26529. Epub 2020 Oct 5. J Med Virol. 2021. PMID: 32949174
-
Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.J Clin Microbiol. 2019 Jan 2;57(1):e01303-18. doi: 10.1128/JCM.01303-18. Print 2019 Jan. J Clin Microbiol. 2019. PMID: 30355757 Free PMC article.
-
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.J Hepatol. 2019 Apr;70(4):615-625. doi: 10.1016/j.jhep.2018.11.030. Epub 2018 Dec 7. J Hepatol. 2019. PMID: 30529504
-
Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients.Gastroenterol Hepatol. 2020 Nov;43(9):526-536. doi: 10.1016/j.gastrohep.2020.03.017. Epub 2020 Sep 10. Gastroenterol Hepatol. 2020. PMID: 32921478 Review. English, Spanish.
-
A critique and systematic review of the clinical utility of hepatitis B core-related antigen.J Hepatol. 2023 Apr;78(4):731-741. doi: 10.1016/j.jhep.2022.12.017. Epub 2022 Dec 28. J Hepatol. 2023. PMID: 36586590
Cited by
-
Serum HBV RNA: a promising biomarker for blood product safety screening and enhanced diagnostic efficiency in chronic hepatitis B virus infection.Front Public Health. 2023 Aug 31;11:1248878. doi: 10.3389/fpubh.2023.1248878. eCollection 2023. Front Public Health. 2023. PMID: 37719720 Free PMC article. No abstract available.
-
Value and Kinetics of Virological Markers in the Natural Course of Chronic Hepatitis D Virus Infection.Liver Int. 2025 Feb;45(2):e70003. doi: 10.1111/liv.70003. Liver Int. 2025. PMID: 39846714 Free PMC article.
-
Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection.Front Public Health. 2022 Oct 28;10:1037508. doi: 10.3389/fpubh.2022.1037508. eCollection 2022. Front Public Health. 2022. PMID: 36388269 Free PMC article.
-
Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B.Front Microbiol. 2022 Jun 22;13:901233. doi: 10.3389/fmicb.2022.901233. eCollection 2022. Front Microbiol. 2022. PMID: 35814664 Free PMC article.
-
A study on pregenomic RNA and factors in the pregnant and postpartum women with chronic HBV infection based on real world.Front Cell Infect Microbiol. 2025 Apr 4;15:1539356. doi: 10.3389/fcimb.2025.1539356. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40256451 Free PMC article.
References
-
- Wong DH, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, et al. Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017;37:995‐1001. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR001111/TR/NCATS NIH HHS/United States
- U54 RR019192/RR/NCRR NIH HHS/United States
- U01 DK082923/DK/NIDDK NIH HHS/United States
- UL1 TR000058/TR/NCATS NIH HHS/United States
- M01 RR000400/RR/NCRR NIH HHS/United States
- U01 DK082867/DK/NIDDK NIH HHS/United States
- U01 DK082874/DK/NIDDK NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- U01 DK082919/DK/NIDDK NIH HHS/United States
- U01 DK082927/DK/NIDDK NIH HHS/United States
- U01 DK082872/DK/NIDDK NIH HHS/United States
- U01 DK082943/DK/NIDDK NIH HHS/United States
- K24 AA022523/AA/NIAAA NIH HHS/United States
- P30 DK050306/DK/NIDDK NIH HHS/United States
- M01 RR000040/RR/NCRR NIH HHS/United States
- U01 DK082871/DK/NIDDK NIH HHS/United States
- U01 DK082944/DK/NIDDK NIH HHS/United States
- U01 DK082864/DK/NIDDK NIH HHS/United States
- U01 DK082843/DK/NIDDK NIH HHS/United States
- U01 DK082863/DK/NIDDK NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- U01 DK082866/DK/NIDDK NIH HHS/United States